Regoes Roland R, Bonhoeffer Sebastian
Institute of Integrative Biology, ETH Zürich, ETH Zentrum CHN K12.1, Universitätsstrasse 16, CH 8092 Zürich, Switzerland.
Science. 2006 Apr 21;312(5772):389-91. doi: 10.1126/science.1122947.
Given the considerable challenges to the rapid development of an effective vaccine against influenza, antiviral agents will play an important role as a first-line defense if a new pandemic occurs. The large-scale use of drugs for chemoprophylaxis and treatment will impose strong selection for the evolution of drug-resistant strains. The ensuing transmission of those strains could substantially limit the effectiveness of the drugs as a first-line defense. Summarizing recent data on the rate at which the treatment of influenza infection generates resistance de novo and on the transmission fitness of resistant virus, we discuss possible implications for the epidemiological spread of drug resistance in the context of an established population dynamic model.
鉴于研发一种有效的抗流感疫苗面临巨大挑战,若新的大流行发生,抗病毒药物将作为一线防御发挥重要作用。大规模使用药物进行化学预防和治疗将对耐药菌株的进化产生强大的选择压力。这些菌株随后的传播可能会大幅限制药物作为一线防御的有效性。总结近期关于流感感染治疗产生新耐药性的速率以及耐药病毒传播适应性的数据,我们在既定的种群动态模型背景下讨论耐药性在流行病学传播方面可能产生的影响。